Skip to main content
. 2015 Jun 12;59(7):3695–3699. doi: 10.1128/AAC.00638-15

FIG 2.

FIG 2

Opinions on the positive impact that changes in regulatory pathways and guidance might have on the successful development of new antibacterial agents. MDRO, multidrug-resistant organism; LPAD, limited-population antibacterial drug; M&S, modeling and simulation.